I think all the long termers need to keep the faith and be conscious of that whilst its not a great SP at present agreed, we should acknowledge where we should be on the current status... We have never been in a more qualified situation to bring home the bacon IMO, & importantly a renewed hope for the individuals within the HT trial for a new chance at a quality life.
We need to survey where we are at now finally in HT, a low tox, qualified NHP, & with a plus 50-70% chance communicated by Management of commercialisation of our first drug, higher probabilities of partnership, & compare this to where we have been at much higher SP's +17's in a much, much lower qualifying & news stage. I thus feel the most confident that I ever have in 12+ years as a shareholder at success & beneficial outcomes for the supporters of PYC.
IMO, I am thinking 20 + mid year on news pos. flow & creeping to end of year news outcomes. I "suspect" a surprise announcement to please all for much higher; this purely based on the data, current stage, & interview comments of partnership probabilities based on data & HT stages to please us all on the ASX.
The language & excitement seen in interviews on the 4 drugs does form some of my current opinion, however the data and senior management & stakeholders % loading also adds. The additional benefits of the AI partnership for additional revenue streams is a +. I remember the days of SP 1c & running on the smell of an oily rag with a 1m grant each year to keep the wheels turning to where we see ourselves today ! WOW, look at us now.
I believe we are in for a bumper crop this year & I hope I'm not proved wrong all ! GLTAH. I'm still buying !
- Forums
- ASX - By Stock
- PYC Chart and Technical Analysis
PYC
pyc therapeutics limited
Add to My Watchlist
4.17%
!
$1.15

I think all the long termers need to keep the faith and be...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.15 |
Change
-0.050(4.17%) |
Mkt cap ! $670.7M |
Open | High | Low | Value | Volume |
$1.18 | $1.20 | $1.15 | $146.7K | 125.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 71742 | $1.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.20 | 11949 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 71742 | 1.150 |
1 | 50000 | 1.140 |
1 | 6756 | 1.130 |
1 | 889 | 1.125 |
3 | 9261 | 1.100 |
Price($) | Vol. | No. |
---|---|---|
1.200 | 11949 | 2 |
1.205 | 2270 | 1 |
1.210 | 6000 | 1 |
1.220 | 5596 | 2 |
1.230 | 15000 | 1 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online